Family · Pharmaceutical analytical standards
Selexipag
A selective prostacyclin IP receptor agonist taken by mouth: it widens the arteries of the lungs and curbs platelet aggregation. Approved in the United States in 2015 and in Europe in 2016 for pulmonary arterial hypertension. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Prostacyclin and its analogues last too briefly in the blood for convenient use; selexipag, a diphenylpyrazine derivative that looks nothing like it, mimics its action and in the body becomes a metabolite 37 times more potent.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
